Obi Umeh, MD, MSc, VP, Franchise Global Program Leader at Takeda, discusses interim results from a study investigating mezagitamab for the treatment of patients with IgA nephropathy. This proof-of-concept study demonstrated the tolerability and favorable safety profile of mezagitamab, an IgG1 monoclonal antibody that leads to depletion of CD38-expressing cells. Notably, mezagitamab also led to a 54.9% mean reduction in proteinuria. Taken together, these results support the development of a phase 3 clinical trial.